Astellas Pharma Inc. (4503.T)
| Previous Close | 1,469.00 |
| Open | 1,470.50 |
| Bid | 1,452.50 x 0 |
| Ask | 1,455.50 x 0 |
| Day's Range | 1,453.00 - 1,484.50 |
| 52 Week Range | 1,426.00 - 2,360.50 |
| Volume | |
| Avg. Volume | 9,081,711 |
| Market Cap | 2.609T |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 551.14 |
| EPS (TTM) | 2.64 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 70.00 (4.77%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | 2,087.10 |
PR NewswireAstellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.
- PR Newswire
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily origin
- PR Newswire
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 27, 2024 the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If appr
